These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 1841807

  • 21. [Cardiovascular risk stratification. Systolic, diastolic or pulse pressure?].
    Pede S, Lombardo M.
    Ital Heart J Suppl; 2001 Apr; 2(4):356-8. PubMed ID: 19397006
    [Abstract] [Full Text] [Related]

  • 22. [Arterial hypertension, left ventricular hypertrophy and cardiovascular risk].
    Nogueira JB.
    Acta Med Port; 1995 Dec; 8(12):663-6. PubMed ID: 8669314
    [No Abstract] [Full Text] [Related]

  • 23. Hypertension and cardiovascular risk assessment in dialysis patients.
    Locatelli F, Covic A, Chazot C, Leunissen K, Luño J, Yaqoob M, Accorde Programme.
    Nephrol Dial Transplant; 2004 May; 19(5):1058-68. PubMed ID: 15004266
    [Abstract] [Full Text] [Related]

  • 24. Microalbuminuria and hypertension.
    Reboldi G, Gentile G, Angeli F, Verdecchia P.
    Minerva Med; 2005 Aug; 96(4):261-75. PubMed ID: 16179893
    [Abstract] [Full Text] [Related]

  • 25. The future role of losartan.
    Hansson L.
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S55-8. PubMed ID: 8583483
    [Abstract] [Full Text] [Related]

  • 26. Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
    de Simone G, Wachtell K, Palmieri V, Hille DA, Beevers G, Dahlöf B, de Faire U, Fyhrquist F, Ibsen H, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Devereux RB.
    Circulation; 2005 Apr 19; 111(15):1924-31. PubMed ID: 15837945
    [Abstract] [Full Text] [Related]

  • 27. [Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in essential hypertension].
    Burnier M.
    Drugs; 2002 Apr 19; 62 Spec No 1():21-9. PubMed ID: 12036386
    [Abstract] [Full Text] [Related]

  • 28. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A, Goicoechea Diezhandiño M, de Alvaro Moreno F.
    Nefrologia; 2008 Apr 19; 28 Suppl 3():39-48. PubMed ID: 19018737
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V, Devereux RB.
    Minerva Cardioangiol; 2002 Jun 19; 50(3):169-74. PubMed ID: 12107398
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The aging hypertensive heart: a brief update.
    Susic D, Frohlich ED.
    Nat Clin Pract Cardiovasc Med; 2008 Feb 19; 5(2):104-10. PubMed ID: 18223542
    [Abstract] [Full Text] [Related]

  • 34. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.
    Dahlöf B.
    Blood Press Suppl; 1994 Feb 19; 2():35-40. PubMed ID: 8061844
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [The cardiac renin-angiotensin system and its role in ventricular hypertrophy associated with arterial hypertension].
    Rubattu S, Volpe M, Raman V, Lindpaintner K.
    Cardiologia; 1997 Jan 19; 42(1):47-50. PubMed ID: 9118154
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.